Rhythm Pharmaceuticals Inc RYTM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $115.48
- Day Range
- $108.22–114.95
- 52-Week Range
- $74.50–122.20
- Bid/Ask
- $105.00 / $139.00
- Shares Outstanding
- 68.59M
- Market Cap
- $7.44B
- Volume/Avg
- 384 / 797,093
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 34.89
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 414
- Website
- https://www.rhythmtx.com
Valuation
|
Metric
|
RYTM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 63.72 |
Price/Sales | 34.89 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RYTM
|
|---|---|
Quick Ratio | 3.63 |
Current Ratio | 4.17 |
Interest Coverage | −9.98 |
Quick Ratio
RYTM
Profitability
|
Metric
|
RYTM
|
|---|---|
Return on Assets (Normalized) | −32.51% |
Return on Equity (Normalized) | −170.32% |
Return on Invested Capital (Normalized) | −61.92% |
Return on Assets
RYTM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%@qkxv | LOCK|y?!h | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|d^ghhYC | LOCK|s^Gt | $70B | |||
| argenx SE ADR
ARGX
| LOCK|kG><wn | LOCK|%%c | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|t>l>sWc | LOCK|%mG? | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|J!L!v<% | LOCK|n? | $36B | |||
| Moderna Inc
MRNA
| LOCK|L@<%D>! | LOCK|GK | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|dh&QR^J | LOCK|?%l&< | $25B | |||
| Incyte Corp
INCY
| LOCK|rMJ#<#F | LOCK|<S< | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|J%YKn< | LOCK|<>S | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|c%@#BRP | LOCK|B^ | $17B |
United States